HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Repurposed Hepatitis C Drugs for COVID-19 Treatment Could Break Life Cycle of Coronavirus

By HospiMedica International staff writers
Posted on 11 Sep 2020
Image: Repurposed Hepatitis C Drugs for COVID-19 Treatment Could Break Life Cycle of Coronavirus (Photo courtesy of University of Washington)
Image: Repurposed Hepatitis C Drugs for COVID-19 Treatment Could Break Life Cycle of Coronavirus (Photo courtesy of University of Washington)
A team of researchers have identified antiviral drugs used to treat hepatitis C that are protease inhibitors and could be repurposed for use as treatment for COVID-19.

Researchers from the University of Washington (UW) Medicine (Seattle, Wash., USA) examined 6,800 known drugs with a history of safe use in humans that could possibly break the life cycle of the coronavirus by blocking an important protein called the main protease. The team singled out boceprevir and narlaprevir, protease inhibitors developed by Merck & Co. that have been superceded by more effective hepatitis C treatments.

The researchers believe that if these drugs prove effective against the novel coronavirus in clinical trials, they can be used as part of a combination therapy to adopt more than one line of attack against the virus. According to the researchers, finding potent treatments among approved drugs offers an advantage as they “can be advanced rapidly to clinical trials without extensive multi-year preclinical development efforts.”

Related Links:
University of Washington

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
ow Frequency Pulse Massager
ET10 L

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more